4-dimention live imaging of inflamatory cells in conjunctiva after glaucoma surgery
Project/Area Number |
25670735
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Ophthalmology
|
Research Institution | Kumamoto University |
Principal Investigator |
|
Project Period (FY) |
2013-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 眼細胞生物学 / 二光子顕微鏡 / 結膜損傷 / 好中球 |
Outline of Final Research Achievements |
We visualized intravital inflammatory cell dynamics in mice conjunctiva in vivo by using two-photon microscopy, and evaluated immuno-reaction after conjunctival invasive interventions. Using LysM-eGFP transgenic mouse, eGFP-labeled inflammatory cells (mainly neutrophil) were tracked and imaged. In conjunctival injury model by 10-0 nylon suturing, eGFP-positive cells were significantly and time-dependently increased compared to non-injured control. Also, the migration velocities of inflammatory cells were rapidly increased by 3 hours after invasion, and sustained until 72 hours. This novel in-vivo live imaging technique may be a useful tool to elucidate the inflammatory/wound healing mechanism in conjunctiva after glaucoma surgery..
|
Report
(3 results)
Research Products
(42 results)
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.2014
Author(s)
Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, Araie M; the K-115 Clinical Study Group.
-
Journal Title
Acta Ophthalmologica
Volume: 93
Issue: 4
Pages: 254-260
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-